CoChat

Stratified cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): impact of varying metabolic risk factor burden

Open access
Elsabaawy, Maha, Torkey, Mohamed, Magdy, Mai, Naguib, Madiha · 2025 · European Journal of Medical Research

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a spectrum of hepatic disorders that are closely linked to metabolic risk factors. This study aimed to investigate the stratified cardiovascular risk in patients with MASLD based on varying metabolic risk burdens. Methods: In a cross-sectional analysis, 357 patients with MASLD were classified into three subtypes based on the number of metabolic conditions used for diagnosis: subtype 1 with one metabolic risk factor (n = 110), subtype 2 with two (n = 161), and subtype 3 with three risk factors (n = 86). Clinical parameters, liver enzymes, lipid profiles, and 10-year risk of Atherosclerotic Cardiovascular Disease (ASCVD) were compared among subtypes. Results: The prevalence of diabetes and hypertension increased significantly across subtypes, with subtype 3 showing the highest burden of cardiovascular risk factors (100% diabetes, 43% hypertension). Cardiovascular risk was elevated in subtype 3 (mean ASCVD 0.112 ± 0.108, p < 0.001). Multivariate analysis identified subtype 3 (OR = 7.812, 95% CI 1.980–30.819, p = 0.003), men sex (OR = 33.549, 95% CI 11.814–95.269, p < 0.001), and age (OR = 1.171, 95% CI 1.116–1.229, p < 0.001) as independent predictors of intermediate to high cardiovascular risk. Conclusion: The metabolic burden in patients with MASLD significantly stratified cardiovascular risk. Patients with the highest metabolic dysfunction are at increased risk of cardiovascular events, underscoring the need for targeted cardiovascular prevention strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40001-025-03151-9

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of enrolled cases
Fig. 1 Flow chart of enrolled casesCC BY · PubMed Central
Fig. 2 Distributions of the three subtypes according to MASLD diagnostic criteria
Fig. 2 Distributions of the three subtypes according to MASLD diagnostic criteriaCC BY · PubMed Central
Fig. 3 Menopausal females and CVR
Fig. 3 Menopausal females and CVRCC BY · PubMed Central
Fig. 4 Physical activity and CVR
Fig. 4 Physical activity and CVRCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 3

  1. Eslam M, El-Serag HB, Francque S, et al. Metabolic dysfunction-associated steatotic liver disease: mechanisms and heterogeneity. Lancet Gastroenterol Hepatol. 2023;8(11):927–43. https://doi.org/10.1016/S2468-1253(23)00183-2. · doi:10.1016/s2468-1253(23)00183-2
  2. Siddiqui MS, Harrison SA, Abdelmalek MF, et al. Ultrasound vs MRI-PDFF for steatosis detection in MASLD. Hepatology. 2023. https://doi.org/10.1097/HEP.0000000000000234. · DOI
  3. Lim S, Lee YH, Kim YJ, et al. Metabolic dysfunction–associated steatotic liver disease predicts long-term mortality and cardiovascular disease. Lancet Gastroenterol Hepatol. 2021;6(9):735–45. https://doi.org/10.1016/S2468-1253(21)00130-2. · doi:10.1016/s2468-1253(21)00130-2

Cited by

See all 14

Metadata

Authors
Elsabaawy, M., Torkey, M., Magdy, M., & Naguib, M.
Affiliations
National Liver Institute (EG)
Corresponding author
Elsabaawy, Maha
Venue
European Journal of Medical Research
Published
2025-09-23
Volume
30
Issue
1
Pages
847-847
ISSN
  • 0949-2321 (ISSN-L)
  • 2047-783X
OpenAlex
W4414413415
Cited by
14
References
32
Citations by year
2026: 12 · 2025: 2
FWCI
9.64
Type
journal article
Language
en
Open access
Licence
Locations
  • European journal of medical research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Minufiya University
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
non-alcoholic fatty liver disease, cardiovascular risk, atherosclerotic cardiovascular disease, metabolic risk factors, diabetes mellitus, hypertension, risk stratification, cardiovascular risk prediction, sex differences, age, cardiovascular disease prevention
MeSH terms
Heart Disease Risk Factors, Adult, Aged, Cardiovascular Diseases, Cross-Sectional Studies, Diabetes Mellitus, Fatty Liver, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stratified cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): impact of varying metabolic risk factor burden. https://app.cochat.ai/papers/10.1186/s40001-025-03151-9
The paper
Elsabaawy, M., Torkey, M., Magdy, M., & Naguib, M. (2025). Stratified cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): impact of varying metabolic risk factor burden. European Journal of Medical Research. https://doi.org/10.1186/s40001-025-03151-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.